{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:26:38Z","timestamp":1794493598771,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Graduate Scientific Research and Innovation Project of Chongqing","award":["CYB240294"],"award-info":[{"award-number":["CYB240294"]}]},{"name":"University Research Project of Army Medical University","award":["ZXZYTSLC04"],"award-info":[{"award-number":["ZXZYTSLC04"]}]},{"name":"University Research Project of Army Medical University","award":["ZXJCYJ202411"],"award-info":[{"award-number":["ZXJCYJ202411"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172807"],"award-info":[{"award-number":["82172807"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13480-8","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T08:20:00Z","timestamp":1754382000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rapid and sustainable deep testosterone reduction predicts effective androgen deprivation therapy for metastatic hormone-sensitive prostate cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Ze","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongliang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianzheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luofu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"13480_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.euf.2017.10.014","volume":"4","author":"SP Kelly","year":"2018","unstructured":"Kelly, S. P., Anderson, W. F., Rosenberg, P. S. & Cook, M. B. Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur. Urol. Focus. 4, 121\u2013127 (2018).","journal-title":"Eur. Urol. Focus"},{"key":"13480_CR2","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.juro.2012.06.046","volume":"188","author":"CM Tangen","year":"2012","unstructured":"Tangen, C. M. et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: A SWOG phase III trial experience (S8494, S8894 and S9346). J. Urol. 188, 1164\u20131169 (2012).","journal-title":"J. Urol."},{"key":"13480_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.eururo.2012.12.004","volume":"63","author":"DE Spratt","year":"2013","unstructured":"Spratt, D. E. et al. Metformin and prostate cancer: Reduced development of castration-resistant disease and prostate cancer mortality. Eur. Urol. 63, 709\u2013716 (2013).","journal-title":"Eur. Urol."},{"key":"13480_CR4","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer. Prostate Cancer Prostatic Diseases 26, \t180\u2013187 (2022).","DOI":"10.1038\/s41391-022-00618-2"},{"key":"13480_CR5","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1007\/s00345-022-04108-x","volume":"40","author":"JC Angulo","year":"2022","unstructured":"Angulo, J. C. et al. Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): Results of the ANARESISTANCE study. World J. Urol. 40, 2459\u20132466 (2022).","journal-title":"World J. Urol."},{"key":"13480_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4103\/1008-682X.174856","volume":"19","author":"Y Wang","year":"2017","unstructured":"Wang, Y., Dai, B. & Ye, D. W. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients. Asian J. Androl. 19, 178\u2013183 (2017).","journal-title":"Asian J. Androl."},{"key":"13480_CR7","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00345-020-03368-9","volume":"39","author":"M Ferro","year":"2021","unstructured":"Ferro, M. et al. Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with international Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies. World J. Urol. 39, 1861\u20131867 (2021).","journal-title":"World J. Urol."},{"key":"13480_CR8","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1097\/JU.0000000000001946","volume":"206","author":"S Tremblay","year":"2021","unstructured":"Tremblay, S. et al. Interpreting testosterone and concomitant prostate specific antigen values during androgen deprivation therapy for recurrent prostate cancer. J. Urol. 206, 1166\u20131176 (2021).","journal-title":"J. Urol."},{"key":"13480_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.radonc.2021.04.018","volume":"160","author":"A Zapatero","year":"2021","unstructured":"Zapatero, A. et al. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. Radiother. Oncol. 160, 115\u2013119 (2021).","journal-title":"Radiother. Oncol."},{"key":"13480_CR10","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.juro.2017.05.072","volume":"198","author":"B Tombal","year":"2017","unstructured":"Tombal, B. et al. Clinical outcomes and testosterone levels following continuous androgen deprivation in patients with relapsing or locally advanced prostate cancer: A post hoc analysis of the ICELAND study. J. Urol. 198, 1054\u20131060 (2017).","journal-title":"J. Urol."},{"key":"13480_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford, P. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur. Urol. 71, 630\u2013642 (2017).","journal-title":"Eur. Urol."},{"key":"13480_CR12","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1200\/JCO.2014.58.2973","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz, L. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: A secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J. Clin. Oncol. 33, 1151\u20131156 (2015).","journal-title":"J. Clin. Oncol."},{"key":"13480_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12935-020-01508-0","volume":"20","author":"S Tian","year":"2020","unstructured":"Tian, S. et al. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: A systematic review. Cancer Cell Int. 20, 409 (2020).","journal-title":"Cancer Cell Int."},{"key":"13480_CR14","doi-asserted-by":"crossref","unstructured":"Tan, Y. G. et al. Serum testosterone levels and testosterone \u2018bounce\u2019 phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer. Urol. Oncol. 39, 829.e829\u2013829.e817 (2021).","DOI":"10.1016\/j.urolonc.2021.04.009"},{"key":"13480_CR15","doi-asserted-by":"crossref","unstructured":"van Winden, L. J. et al. Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer. Urol. Oncol. 41, 104-e11(2022).","DOI":"10.1016\/j.urolonc.2022.09.027"},{"key":"13480_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737\u2013746 (2015).","journal-title":"N. Engl. J. Med."},{"key":"13480_CR17","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group. J. Clin. Oncol. 26, 1148\u20131159 (2008).","journal-title":"J. Clin. Oncol."},{"key":"13480_CR18","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.juro.2007.05.129","volume":"178","author":"J Morote","year":"2007","unstructured":"Morote, J. et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J. Urol. 178, 1290\u20131295 (2007).","journal-title":"J. Urol."},{"key":"13480_CR19","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/00000658-194206000-00030","volume":"115","author":"C Huggins","year":"1942","unstructured":"Huggins, C., Effect of orchiectomy and irradiation on cancer of the prostate. Ann. Surg. 115, 1192\u20131200 (1942).","journal-title":"Ann. Surg."},{"key":"13480_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","volume":"36","author":"MH Tan","year":"2015","unstructured":"Tan, M. H., Li, J., Xu, H. E., Melcher, K. & Yong, E. L. Androgen receptor: Structure, role in prostate cancer and drug discovery. Acta Pharmacol. Sin. 36, 3\u201323 (2015).","journal-title":"Acta Pharmacol. Sin."},{"key":"13480_CR21","first-page":"161","volume":"74","author":"D Mitropoulos","year":"2021","unstructured":"Mitropoulos, D., Chlosta, P., H\u00e4ggman, M., Str\u00f6m, T. & Markussis, V. Androgen deprivation monotherapy usage in non-metastatic prostate cancer: Results from eight European countries. Cent. Eur. J. Urol. 74, 161\u2013168 (2021).","journal-title":"Cent. Eur. J. Urol."},{"key":"13480_CR22","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.juro.2015.03.120","volume":"194","author":"S Kamada","year":"2015","unstructured":"Kamada, S. et al. Nadir testosterone after long-term followup predicts prognosis in patients with prostate cancer treated with combined androgen blockade. J. Urol. 194, 1264\u20131270 (2015).","journal-title":"J. Urol."},{"key":"13480_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.clgc.2013.01.002","volume":"11","author":"V Bertaglia","year":"2013","unstructured":"Bertaglia, V. et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin. Genitourin. Cancer. 11, 325\u2013330 (2013).","journal-title":"Clin. Genitourin. Cancer"}],"updated-by":[{"DOI":"10.1038\/s41598-026-59181-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13480-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13480-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13480-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:01:30Z","timestamp":1782460890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13480-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13480"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13480-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-59181-8","URL":"https:\/\/doi.org\/10.1038\/s41598-026-59181-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Committee for Ethics of Daping hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}],"article-number":"28497"}}